Background Highly active antiretroviral therapy (HAART) has
I n the last two decades, Indonesia has seen a concentrated HIV epidemic expand into a generalized one, as a result of the growing number of women of childbearing age who are infected with HIV. 1, 2 The cumulative number of children under 15 years of age with HIV in Indonesia from 1987 to 2014 was reported to be as many as 1,647, of whom 1,206 were under the age of five years. 3 The World Health Organization (WHO) noted that only 21-25% of children infected with HIV received antiretroviral therapy. 4 Although HAART improves the survival of children with HIV, optimizing health and quality of life of pediatric survivors remains a major challenge. 5 Without effective treatment, an estimated one-third of children with HIV die in the first year of life, and about half die in the second year. 6 Several studies reported growth improvements in children with HIV after HAART initiation. Mwiru et al. found that children with HIV showed improvement in metabolism in the first 6 months of HAART. 7 Similarly, Suryani et al. 8 observed growth improvement for 12 months, and Sari et al. showed growth improvement at 24 months of HAART. 9 Although studies have reported growth and nutritional care improvements within 2 years of HAART, other studies noted that stunting may occur after such time. 7, 10, 11 A study of 225 HIV-infected children found a probability of 58% for growth reversal among 179 subjects with growth failure at entry, while the rest remained in growth failure. Age, sex, and clinical category at the time of ART initiation were not risk factors for reversal. 12 Therefore, we aimed to assess if non-reversal of stunting occurred in children with HIV after three years of HAART and to examine risk factors for non-reversal of stunting.
Methods
The study was a part of a prospective cohort study which followed children with HIV who initiated HAART between January 2009 and April 2014, in particular, those with stunting. The study was conducted from May 2016 until April 2017 in the Allergy Immunology Division, Department of Child Health, Sanglah Hospital, Denpasar, Bali. Subjects were part of the eligible population who met the following inclusion criteria. Children with HIV aged < 18 years, good HAART compliance, stunted at the time of HIV diagnosis, and whose parents were willing to participate. Exclusion criteria were lost to follow up or died during observation. In addition to HAART, all children received daily zinc supplementation.
We collected subjects' age, sex, weight, height, height-for-age z-score (HAZ) to determine stunting, recent opportunistic infection, recent anemia, CD4+, nutritional status, family economic status, HIV clinical stage at the start of ART, and 3 years of data to determine linear growth pattern, and risk factors for non-reversal of stunting. All data were collected from the subjects' medical records. The variables were defined as follows:
Stunted: HAZ <-2SD according to the WHO • Child Growth Standard. 13 15 Nutritional status: determined using the Water-• low formula, in which actual body weight was divided by ideal body weight. Ideal body weight was determined using the WHO Growth Chart for body weight over height. 16 Family economic status: the economic ability • to meet the needs of all family members. Our subjects were assumed to have similar economic status, since all subjects used government health care insurance. HIV clinical stage: determined based on the • WHO clinical stage category. 15 Non-reversal of stunting: HAZ <-2SD after 3 • years of HAART. Characteristics of subjects were presented descriptively in tables for the variables of age, sex, and HIV clinical stage, as well as tuberculosis, anemia, chronic diarrhea, CD4+, and nutritional status. Linear growth patterns during 3 years of HAART was presented as a graph. We calculated the proportion of non-reversal of stunting in our subjects. Possible risk factors for non-reversal were analyzed by Chisquare test. Covariates were considered for inclusion in the multivariate model if one or more categories exhibited a P value <0.1 in the bivariate model and were retained if 1 or more categories exhibited a P value <0.05 in the adjusted model. 17 Risk ratio (RR) of associated factors was determined with 95% CI. Analyses were done with SPSS version 18 software. This study was approved by the Medical Ethics Committee of Universitas Udayana/Sanglah Hospital, Denpasar.
Results
A total of 150 children were in the data cohort. Of these, 118 children were alive and 115 children had received HAART. At baseline, 55 (47.8%) children were stunted at HAART initiation, hence, they were included in our study. Only 23 (41.8%) subjects achieved growth reversal after 3 years of HAART initiation. Characteristics of the 55 subjects are shown in Table 1 .
The mean HAZs during the follow up period are shown in Figure 1 . Upon on HAART initiation, mean HAZ improved for the first 6 months, then stabilized with only minimal improvements in linear growth over the 3 years of HAART. The trajectory of HAZ over the 3-year observation tended to plateau. Table 2 shows the factors associated with nonreversal of stunting. Multivariate Cox regression analysis of the 55 children who were stunted at baseline revealed that the strongest predictors for non-reversal of stunting were age>2 years (RR 16.05; 95%CI 2.89 to 89.02; P=0.002) and HIV stage III-IV at HAART initiation (RR 8.93; 95%CI 1.47 to 54.37; P=0.017).
Discussion
Stunting is defined as height for age below minus 2 SD, according to The WHO Child Growth Standard. Stunting indicates a failure to achieve potential linear growth as a result of suboptimal health and/or nutritional conditions. 13 Children with HIV infection have a higher risk of stunting compared to uninfected children. In Tanzania, 36.6% of children infected with 18 The age of 6 to 24 months is the most critical period for linear growth in children, and the time of peak incidence of stunting in children in developing countries. 19 In this study from a database of 150 children with HIV infection, we found 36.7% children with stunting at time of HAART initiation. Similarly, Aurpibul et al. 10 reported 42% in Thailand, but an African study found an even higher proportion of children with stunting, 76.3%. 12 The goal of administering HAART to HIVinfected children is to prolong life and ensure that they achieve sustained growth and development. 19 In a Dar es Salaam study in 2004, HIV-positive children without ART therapy had a higher proportion of stunting. 14 Prendergast et al. assumed that the phenomenon of stunting occurred due to a state of low-grade inflammation, due to HIV infection as a result of enteropathy. 20 HIV infection may result in stunting, despite having good nutrition and a normally functioning endocrine system. Several studies described positive short-term responses of HAZ to ART. 21 Kabue et al. found that administering ART resulted in improvement in HAZ in all subjects who had at least 6 months Of follow-up, and again at 12 months follow-up, respectively. 22 Similar results were found by Suryani et al., 8 who observed children with HIV infection for 12 months, and Sari et al., 9 who observed children with HIV infection for 24 months.
However, few studies reported a growth response to ART beyond 24 months. 22 Sutcliffe et al. reported that after starting ART, nutritional status improved in both weight and height, but even after two years of ART, approximately 50% of children remained stunted. 23 With a longer period of observation, we found that in 58.2% of children, stunting was not reversed, despite receiving ART for 3 years. Mwiru et al. also reported that after ART initiation, child anthropometry z-score profiles improved, however, HAZ scores did not reach the normal value even after 6 years of follow up. 7 Some factors were associated with reversal of growth failure. Aurpibul et al. found that a nevirapinebased regimen was a significant predictor of reversal of growth failure after initiating ART. 12 In our study, all subjects received WHO-recommended firstline, antiretroviral drugs in the form of two NRTIs and one NNRTI, including zidovudine, lamivudine and nevirapine. Children with HIV infection may have underlying chronic conditions or opportunistic infections, including anemia, tuberculosis, and chronic diarrhea, all of which can result in growth faltering by inadequate food intake and increased resting energy expenditure. 22 Diarrhea is the most common chronic condition among HIV-infected children, causing acute weight loss through water and electrolyte loss, leading to poor growth.14 Diarrhea was associated with weight-forage z-scores (WAZ)<-2SD. 14 However, we found that anemia, tuberculosis, chronic diarrhea, and malnutrition at the time of ART initiation were not associated with non-reversal of stunting in this population. Similarly, Mwiru et al. found that anemia, tuberculosis, and chronic diarrhea were not associated with growth outcome. 7 Age >2 years at HAART initiation was a significnt predictor of non-reversal of stunting in our study, similar 7 Better growth outcomes among younger children could be related to the duration of infection, allowing them to more effectively absorb nutrients after viral suppression by ART. The longer duration of HIV infection in older children may further require more time to reserve the damage, implying a more prolonged metabolic cost. 7, 24 Sunguya et al. found that advanced HIV stage was a risk factor for stunting. At advanced stages, a child may succumb to poor linear growth, even with adequate food availability, due to frequent opportunistic infections. These severe opportunistic infections may lead to increased energy expenditure at rest. 14 This result was similar to our finding that stage 3 and 4 HIV at HAART initiation was a significant risk factor for non-reversal of stunting. In contrast, Diniz et al. reported a greater height catch-up after starting HAART in subjects with clinically advanced disease at baseline. 25 A limitation of our study was not including parental, family, or caregiver data, as another study found that family situation was related to growth.26 In conclusion HAART initiation at age >2 years and HIV clinical stage III-IV at diagnosis are risk factors for non-reversal of stunting after 3 years of HAART.
